• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A purification method for GBS type II capsular polysaccharide, in which the capsular polysaccharide is filtered using a membrane with a cutoff of less than 30 kDa. This process provides a higher yield than the previous protocols.
    公开号:BE1023297B1
    申请号:E2015/5825
    申请日:2015-12-17
    公开日:2017-01-26
    发明作者:Francesco Berti；Paolo Costantino；Maria Rosaria Romano
    申请人:Glaxosmithkline Biologicals S.A.；
    IPC主号:
    专利说明:

    PURIFICATION OF STREPTOCOCCAL CAPSULAR POLYSACCHARIDE
    The present application claims the benefit of European Patent Application 14199441.8 (filed December 19, 2014), the full contents of which are hereby incorporated by reference for all intents and purposes.
    TECHNICAL FIELD The invention lies in the field of the purification of bacterial capsular polysaccharides, in particular those of the strain Streptococcus agalactiae, and in particular for use in the preparation of vaccines.
    State of the art
    Capsular polysaccharides are important immunogens found on the surface of bacteria involved in a variety of bacterial diseases. This feature has made them an important component in vaccine design. They have been shown to be useful in inducing immune responses, particularly when bound to carrier proteins (Ref 1).
    Reference 2 describes a process for the preparation of capsular polysaccharides, in particular those of the strain Streptococcus agalactiae (also called Lancefield group B streptococcus or GBS). The method comprises: (a) providing a crude isolate containing the capsular polysaccharide; (b) removing an alcoholic precipitate formed by contacting the crude isolate with an alcoholic solution; (c) ultrafiltration using a cellulose membrane having a cutoff of about 30 kDa to remove smaller molecular weight components while retaining the capsular polysaccharide; (d) removing protein contaminants with a protein-adhering filter; (e) re-N-acetylation of the purified capsular polysaccharide; and (f) ultrafiltration using a cellulose membrane having a cutoff of about 30 kDa again. Summary of the invention
    The inventor (s) purified a type II GBS capsular polysaccharide according to the method of Ref. 2 and found that the process only yielded less than 50%. As a result, there is a need for an improved purification method that produces a higher yield of capsular polysaccharide, particularly for type II GBS capsular polysaccharide. The invention is based on the discovery that a membrane with a cutoff threshold of 10 kDa gives in comparison with 30 kDa in step (f) of Ref. 2 a higher yield, for example about 90%. Without wishing to be bound by any theory, the increase in yield appears to be caused by a more linear conformation of the GBS type II capsular polysaccharide compared to other GBS capsular polysaccharides (eg types Ia, Ib, III and V). The more linear conformation results in reduced steric hindrance and lower hydrodynamic radius, which means that the polysaccharide is prone to leak through a membrane with a higher molecular weight cutoff.
    The inventors have also discovered that good yields of type II GBS capsular polysaccharide can be obtained with a process which does not require a chromatographic step and, in particular, does not require hydrophobic interaction chromatography (HIC).
    Accordingly, the invention is directed to a method of purifying a type II GBS capsular polysaccharide comprising a filtration step that utilizes a membrane with a cutoff threshold of less than about 30 kDa. The invention also provides, in a process for purifying a type II GBS capsular polysaccharide, the improvement of using a membrane having a molecular weight cut-off of less than about 30 kDa for a filtration step at instead of a membrane having a molecular weight cutoff of about 30 kDa. The filtration step may use a membrane having a cut-off threshold <25 kDa, for example <20 kDa, <15 kDa or <10 kDa. Preferably, the filtration step uses a membrane having a cutoff of 10 kDa. The filtration step will be discussed in more detail below.
    Typically, one or more additional steps are carried out before the filtration step. Suitable steps include: (a) providing a crude isolate containing the capsular polysaccharide; (b) removing an alcoholic precipitate formed by contacting the crude isolate with an alcoholic solution; and (c) removing protein contaminants with a protein-adhering filter.
    In some embodiments, one or more additional steps may be performed after the filtration step. For example, the additional steps may be: (e) precipitation of the purified capsular polysaccharide; (f) conjugating the capsular polysaccharide with a carrier protein, for example, diphtheria toxoid, tetanus toxoid or CRM197; (g) formulating a vaccine with the capsular polysaccharide as a component; and / or (h) mixing with one or more capsular polysaccharides from a serotype GBS-selected from the group consisting of types Ia, Ib, III, IV, V, VI, VII and VIII, in particular wherein these capsular polysaccharides are or are conjugated with one or more carrier proteins, for example diphtheria toxoid, tetanus toxoid or CRM197.
    The process may comprise more than one filtration step. In such a case, it is typically the final filtration step that uses a membrane with a cut-off of less than about 30 kDa. The invention also provides a composition comprising a type II GBS capsular polysaccharide obtainable by the purification method of the invention.
    Brief description of the drawings
    Fig. 1 represents the molecular structure of a type II serotype specific GBS capsular polysaccharide.
    Fig. 2 represents a process for purifying a type II GBS capsular polysaccharide.
    Detailed Description of Preferred Embodiments
    Capsular saccharide
    The GBS-related diseases are mainly serotypes Ia, Ib, II, III, IV, V, VI, VII and VIII, more than 90% of which are caused by five serotypes: la, Ib, II, III and V The capsular polysaccharide of the strain S. agalactiae is covalently bound to GlcNAc residues in the peptidoglycan backbone of the bacterium and is distinct from the group B antigen, which is a separate saccharide which is attached to residues of MurNAc on the same peptidoglycan skeleton ([3]). Capsular polysaccharides of different serotypes are chemically related, but are very antigenically different. All GBS capsular polysaccharides share the same trisaccharide core as follows:
    The various GBS serotypes differ in the way this heart is modified. The invention uses GBS that belong to serotype II. Preferably, the invention uses any type II GBS strain that expresses a reasonable amount of capsular polysaccharide to complete the purification, for example 18RS21 or DK21.
    As shown in FIG. 1, GBS type II capsular saccharide comprises: (a) a terminal N-acetylneuraminic acid (NeuNAc) residue (commonly referred to as sialic acid), which in all cases is bound 2-> 3 to a residue of galactose; and (b) a residue of N-acetylglucosamine (GlcNAc) in the trisaccharide core. The trisaccharide core of GBS type II capsular polysaccharides contains three galactose residues per repeating unit.
    The purified saccharides according to the invention will generally be in their natural form, but they may have been modified. For example, the saccharide may be shorter than the natural capsular saccharide or may be chemically modified. For example, it can be modified to produce unnatural capsular polysaccharides or heterologous polysaccharides or to increase yield.
    As a result, the saccharide used according to the invention may be a substantially full-length capsular polysaccharide, as found in nature, or it may be shorter than the natural length. Full length polysaccharides can be de-polyesterized to give shorter fragments for use with the invention, for example, by hydrolysis in mild acid by heating, exclusion chromatography, etc. Chain length has been reported to affect the immunogenicity of GBS saccharides in rabbits [4].
    The saccharide can be chemically modified with respect to the capsular saccharide, as found in nature. For example, the saccharide may be de-O-acetylated (in part or in whole), de-N-acetylated (in part or in whole), N-propionate (in part or in whole), etc. Depending on the particular saccharide, deacetylation may or may not affect immunogenicity, for example, NeisVac-C ™ vaccine uses de-O-acetylated saccharide, while Menjugate ™ is acetylated, but both vaccines are effective. The importance of O-acetylation on GBS saccharides in various serotypes is discussed in reference 5 and it is preferred to maintain O-acetylation of sialic acid residues at positions 7, 8 and / or 9 before, during, and after purification, for example using formaldehyde for saccharide extraction and / or bacterial inactivation, by protection / deprotection, by reacetylation, etc. The effect of deacetylation, etc. can be evaluated by routine tests.
    Purification process
    The purification process typically contains several steps, as will be explained in more detail below. The steps typically take place in the order described below, although other orders may also be effective.
    Material of departure
    Methods for preparing capsular saccharides from bacteria are well known in the art, for example refer to references 6, 7, 8, etc. For GBS, the following methods may be used (see also Ref 9).
    The purification process of the invention can start with a crude isolate containing the type II GBS capsular polysaccharide. The capsular saccharide is in aqueous form, typically in the form of a suspension comprising streptococcal proteins, nucleic acids and capsular polysaccharide.
    In general, a small amount of capsular polysaccharide is released into the culture medium during bacterial growth and, thus, the starting material for the alcoholic precipitation of contaminating proteins and / or nucleic acids can therefore to be the supernatant of a centrifuged bacterial culture. For example, in some embodiments, the polysaccharide may be isolated from the bacterium Streptococcus agalactiae which comprises mutations in cpsA (uniprot access number Q9RPC7) and / or cpsD (uniprot access number K0JNC2) and secretes large amounts of capsular polysaccharide in the culture medium. Suitable mutants and mutations are disclosed in International Patent Application No. PCT / EP2015 / 059773 (published as WO2015 / 169774) incorporated by reference herein. More typically, however, the starting material will be prepared by treating the encapsulated bacteria themselves (or the bacterial peptidoglycan-containing material) so that the capsular saccharide is released.
    The capsular polysaccharide can be released from bacteria by various methods, including chemical, physical or enzymatic treatment. As a result, an aqueous polysaccharide preparation can be treated prior to the initial precipitation reaction of the protein and the nucleic acid.
    Typical chemical treatment is extraction with a base [10] (eg using sodium hydroxide) which can cleave the phosphodiester bond between the capsular saccharide and the peptidoglycan backbone. Extraction with a base is advantageous because it inactivates the bacterium at the same time as it releases the capsular polysaccharide. In addition, the base treatment releases the intact polysaccharide and causes extensive cleavage of the B-group antigen due to its multiple phosphodiester [3] bonds, which facilitates the subsequent separation of capsular saccharide and antigen-specific antigens. group. Sodium hydroxide treatment is therefore a preferred method for releasing the capsular polysaccharide. The inventors have found that treatment with sodium hydroxide using 0.8 M NaOH at 37 ° C for 36 hours was particularly useful with the process of the invention. As treatment with de-N-acetylated hydroxide capsular saccharide, however, subsequent re-N-acetylation may be useful.
    Typical enzymatic treatment involves the use of both mutanolysin and β-N-acetylglucosaminidase [3]. These act on the peptidoglycan GBS to release the capsular saccharide for use with the invention, but also lead to the release of the group-specific carbohydrate antigen. Another enzymatic treatment involves treatment with a phosphodiesterase type II (PDE2). PDE2 enzymes can cleave the same phosphates as sodium hydroxide (see above) and can release capsular saccharide without cleaving the group-specific carbohydrate antigen and without de-N-acetylating the capsular saccharide, which has the effect of simplifying the steps downstream. PDE2 enzymes are therefore a preferred option for preparing GBS capsular saccharides for use in the method of the invention.
    A preferred starting material for the process of the invention is therefore a de-N-acetylated capsular polysaccharide which can be obtained by extraction with a base as described in reference 10. Another preferred starting material is therefore the product of PDE2 treatment of GBS. These materials may be subjected to concentration (eg ultrafiltration) prior to precipitation by the process of the invention.
    Alcoholic precipitation and cation exchange
    The type II GBS capsular saccharide obtained after culturing will generally be impure and will be contaminated with nucleic acids and bacterial proteins. The process of the invention can use an alcoholic precipitation. If necessary (for example after extraction with a base), the materials will usually be neutralized before precipitation. The alcohol used to precipitate nucleic acids and / or contaminating proteins is preferably a lower alcohol, such as methanol, ethanol, propan-1-ol, propan-2-ol, butan-1 ol, butan-2-ol, 2-methyl-propan-1-ol, 2-methyl-propan-2-ol, diols, etc. Selection of a suitable alcohol can be empirically tested without undue burden, but alcohols such as ethanol and isopropanol (propan-2-ol) are preferred over alcohols such as phenol. The alcohol is preferably added to the polysaccharide slurry to give a final alcohol concentration of between 10% and 50% (e.g., about 30%). The most useful concentrations are those that allow adequate precipitation of contaminants without also precipitating the polysaccharide. The optimal final alcohol concentration may be dependent on the strain of GBS from which the polysaccharide is drawn and may be determined by routine tests without undue burden. Precipitation of polysaccharides at ethanol concentrations above 50% was observed.
    In some embodiments, the alcohol solution is added in sufficient concentration to precipitate the nucleic acid contaminants, but not the capsular polysaccharide. In preferred embodiments, the alcohol is ethanol preferably added at a concentration of from about 10% to about 50%, more preferably at a concentration of about 30% ethanol. The inventors have discovered that an alcohol precipitation step which involves the addition of ethanol in a concentration of about 30% ethanol was particularly useful with the process of the invention.
    The alcohol solution may optionally include a cation, preferably a metal cation, more preferably a divalent cation, most preferably calcium. The alcohol may be added in pure form or may be added in diluted form with a miscible solvent (eg water). Preferred solvent mixtures are mixtures of ethanol and water with a preferred ratio of from about 70:30 to about 95: 5 (eg, 75:25, 80:20, 85:15, 90:10). .
    The saccharide is also treated with an aqueous metal cation. Monovalent and divalent metal cations are preferred and divalent cations are particularly preferred, especially Mg ++, Mn ++, Ca ++, etc., as they are more effective in complex formation. Calcium ions are particularly useful and in particular the alcohol mixture preferably comprises soluble calcium ions. These can be added to a mixture of saccharide and alcohol in the form of added calcium salts in solid form or in aqueous form. Calcium ions are preferably provided by the use of calcium chloride.
    The calcium ions are preferably present in a final concentration of between 10 and 500 mM, for example about 0.1 M. The optimal final Ca ++ concentration may depend on the GBS serotype from which the polysaccharide is drawn and may be determined by routine tests without exaggerated load. Alcohol and cation play different roles (alcohol is used to precipitate contaminants, while cation stabilizes and complexes saccharide in soluble form), but produces a combined effect. Although the purpose is to prepare a mixture of saccharide, alcohol and cation, these three components do not have to be mixed together simultaneously. As a result, the alcohol and the cation can be used sequentially or simultaneously. Sequential processing is preferred and a particularly preferred method involves adding the cation to the saccharide followed by the addition of the alcohol to the cation and saccharide mixture, although the alcohol can be used before the cation if desired. .
    After alcoholic precipitation of contaminating proteins and / or nucleic acids, the GBS capsular polysaccharide is left in solution. The precipitated material may be separated from the polysaccharide by any suitable means, in particular by centrifugation. The supernatant may be subjected to microfiltration and, in particular, to frontal filtration (perpendicular filtration) to remove particles which may clog the filters at the subsequent stages (for example, precipitated particles with a diameter greater than 0.22 μπι ). As another solution to frontal filtration, tangential microfiltration can be used.
    Filtration Step The invention involves a filtration step using a membrane with a cutoff threshold of less than about 30 kDa. The method can utilize a membrane having a cut-off threshold of 25 kDa, for example 20 20 kDa, <15 kDa or <10 kDa. Preferably, the filtration step uses a membrane with a cut-off of 10. kDa. The filtration membrane allows the passage of hydrolysis products while retaining the capsular polysaccharide. The invention may use more than one filtration step. For example, the process may comprise: (i) one or more filtration steps (eg, 2, 3, 4, 5, 6, etc.) after the alcoholic precipitation and cation exchange step described above and before filtration with a protein-adhering filter described below and (ii) a filtration step after filtration with a protein-adhering filter, wherein the filtration step of (ii) is that which uses a membrane with a cutoff threshold of less than about 30 kDa. Alternatively, all filtration steps use a membrane with a cutoff of less than about 30 kDa, especially <10 kDa.
    In at least one filtration step of the invention (typically, the final filtration step, for example step (ii) above), the membrane of the filtration step has a cutoff threshold of less than about 30 kDa (e.g., 25 25 kDa, 20 20 kDa, 15 15 kDa or 10 10 kDa). In the other filtration steps (e.g. in step (i) above), a cutoff threshold in the range of about 10 kDa to 30 kDa may be useful. Smaller cleavage sizes can be used because the hydrolysis fragments of the group-specific antigen are generally about 1 kDa (5-mer, 8-mer and 11-mer saccharides), but the Higher cleavage advantageously allows the removal of other contaminants without leading to leakage of the capsular saccharide. The invention may be a process comprising more than one filtration step and the filtration step that uses a membrane with a cutoff threshold of less than about 30 kDa is the final filtration step. The process may comprise more than two filtration steps and the filtration step that uses a membrane with a cutoff of less than about 30 kDa is the final filtration step. In particular, the final filtration step can use a membrane with a cut-off of about 10 kDa. In particular, the method may comprise: (i) a filtration step that uses a membrane with a cut-off of less than about 30 kDa; (ii) another filtration step that uses a membrane with a cut-off of less than about 30 kDa; and (iii) another filtration step that uses a membrane with a cutoff of about 10 kDa.
    In particular, the invention may be a process comprising one or more or all of the following steps: (i) a filtration step which uses a 0.65 μπι membrane; (ii) a filtration step that uses a membrane with a cut-off of less than about 30 kDa; (iii) a filtration step which uses a 0.45 to 0.22 μm membrane; (iv) a filtration step that uses a membrane with a cut-off of less than about 30 kDa; (v) a filtration step that uses a protein-adhering filter; (vi) a filtration step that uses a membrane with a cutoff of about 10 kDa; (vii) a filtration step that uses a 0.22 μm disposable syringe filter. The filtration step may be an ultrafiltration step. Ultrafiltration is a separation process in which a solvent is removed from a solution (especially a colloidal solution) or suspension by forcing it to flow through a membrane by applying hydraulic pressure. Components of the solution that are significantly larger than the pores of the membrane can not pass through the membrane. Ultrafiltration is preferably cross-flow or tangential flow ultrafiltration. In tangential flow ultrafiltration, the solution flows substantially parallel to the surface of the membrane instead of flowing perpendicular to the surface as in ordinary filtration. Tangential flow diafiltration is typical. The ultrafiltration step preferably results in the diafiltration of the solution. In the diafiltration, the solvent and / or microsolutes (eg salts) which are removed during ultrafiltration are replaced by a new solvent and new microsolutes. In general, the elimination and replacement occur at the same rate and the volume of the solution is kept constant. The overall effect of the process is therefore the replacement of the solvent and the initial microsolutes by new solvents / microsolutes. The new solvents / microsolutes may be any suitable buffer, for example a Tris buffer, NaPi buffer or Na2CO3 buffer.
    Typically, each diafiltration step replaces the buffer with a different buffer. For example, when the process of the invention involves the use of two or more diafiltration steps, for example (i) one or more diafiltration steps (eg, 2, 3, 4, 5, 6, etc.). after the alcoholic precipitation and cation exchange step described above and before filtration with a protein-adhering filter described below and (ii) a diafiltration step after filtration with a protein-adherent filter, the diafiltration step (s) in (1) replaces (s) the buffer (for example a Tris buffer) with a different buffer (for example a NaPi buffer) and the diafiltration step in (ii) replaces the buffer ( for example, a buffer of NaPi) with another buffer (for example, a KPi buffer). Preferably, the diafiltration step (s) in (i) use (s) a membrane with a cutoff threshold of about 30 kDa and the diafiltration step in (ii) uses a membrane with a cutoff threshold of less than about 30 kDa (for example, ≤25 kDa, ≤20 kDa, ≤15 kDa or ≤10 kDa).
    In some embodiments, step (i) comprises two diafiltration steps. In this case, the first diafiltration step replaces the buffer (for example a Tris buffer) with a different buffer (for example a NaPi buffer) and the second diafiltration step replaces the buffer (for example a NaPi buffer) with another buffer (for example a Na 2 CO 3 buffer). Preferably, the two diafiltration steps in (i) use a membrane with a cutoff threshold of about 30 kDa and the diafiltration step in (ii) uses a membrane with a cutoff of less than about 30 kDa (e.g. ^ 25 kDa, ^ 20 kDa, ^ 15 kDa or ^ 10 kDa).
    At least 5 diafiltration cycles are usually performed, for example 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or more. The number of diafiltration cycles may differ at different stages of diafiltration. For example, when the process of the invention involves the use of two or more diafiltration steps, for example (i) one or more diafiltration steps (eg, 2, 3, 4, 5, 6, etc.). after the alcoholic and cation exchange precipitation step described above and before filtration by a protein-adhering filter described below and (ii) a diafiltration step after filtration with a protein-adhering filter, the number of diafiltration cycles (i) and (ii) may be different. For example, the invention can use an x number of cycles in the diafiltration step of (i) and a number y of cycles in the diafiltration step of (ii). x and y may be independently 5, e.g. 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or more. Preferably, x <y. Preferably, x = 6 and y = 16. Preferably, the diafiltration step of (i) uses a membrane with a cutoff threshold of about 30 kDa and the diafiltration step of (ii) uses a membrane with a cutoff of less than about 30 kDa (for example <25 kDa, <20 kDa, <15 kDa or <10 kDa).
    A diafiltration step preferably lasts less than 10 hours, for example between 2 and 6 hours, more preferably between 3 and 5 hours, for example between 3.5 and 4.5 hours.
    The filtration membranes may be made of any suitable material, for example membranes of cellulose, polyethersulfone or regenerated cellulose.
    Preferably, the final filtration step of the process of the invention is an ultrafiltration step which results in diafiltration and which uses a cellulose membrane with a cutoff threshold of 10 kDa.
    Filtration with a filter adhering to proteins
    The purification of the capsular polysaccharides may further comprise a step in which the protein and / or DNA contaminants are removed by filtration with a filter, for example a protein-adhering filter to which the proteins and / or DNA adhere, but to which the capsular polysaccharide does not adhere or adhere weakly.
    The protein-adhering filter typically comprises activated carbon (for example in the form of a granular carbon bed or a block of pressed or extruded coal) which acts as a filter for the purification of the sample. Typically, a charcoal filter for use in the present invention contains activated charcoal immobilized in a matrix. The matrix may be any porous filter media permeable to the sample.
    The matrix may comprise a support material and / or a binder material. The support material may be a synthetic polymer or a naturally occurring polymer. Suitable synthetic polymers include polystyrene, polyacrylamide and poly (methyl methacrylate), while polymers of natural origin may include cellulose, a polysaccharide and dextran, agarose. Typically, the polymeric support material is in the form of a fibrous network to provide mechanical rigidity. The binder material can be a resin. The matrix may be in the form of a membrane sheet.
    Typically, activated charcoal immobilized in the matrix may be in the form of a cartridge. A cartridge is an autonomous entity containing activated powdered charcoal immobilized in the matrix and prepared in the form of a membrane sheet. The membrane sheet may be captured in a permeable plastic carrier to form a disk. Alternatively, the membrane sheet may be spirally wound. To increase the specific surface area of the filter, various disks can be stacked on top of one another. In particular, the disks stacked on top of each other have a central pipe for collecting and removing the carbon-treated sample from the filter. The configuration of stacked disks can be lenticular.
    Charcoal activated in the charcoal filter can be drawn from different raw materials, for example peat, lignite, wood or coconut husks. Any method known in the art, such as steam treatment or chemical treatment, may be used to activate coal.
    In the present invention, activated carbon immobilized in a matrix can be placed in a housing to form an independent filtration unit. Each filtration unit has its own inlet and outlet for the sample to be purified. Examples of filtration units that are used in the present invention include coal cartridges from Cuno Inc. (Meriden, USA) or Pall Corporation (East Hill, USA).
    Preferably, the invention uses CUNO zetacarbon ™ type filters. These carbon filters comprise a cellulose matrix in which activated carbon powder is trapped and bonded in place by resin.
    Re-N-acetylation
    When the starting material is treated with extraction by a base, for example a treatment with a hydroxide (see above), the process of the invention may comprise an N-acetylation step for re-N-acetylating the saccharide capsular.
    The inventors have discovered that an N-acetylation step which uses a controlled solution of acetic anhydride in the following proportions was particularly useful with the process of the invention: 4.15 mL of acetic anhydride per L, with a ratio of 1: 1 acetic anhydride to ethanol.
    Other treatment of capsular polysaccharide
    The polysaccharide can still be treated to remove contaminants. This is particularly important in situations where even minor contamination is not acceptable (for example, for the production of human vaccines).
    Another preferred step is a precipitation step. For example, the precipitation may use an aqueous cationic solution. The precipitated saccharide can then be separated from any remaining aqueous contaminants, for example by centrifugation. The precipitated material is stable and can be stored for future use. The precipitation step may use AcONa. In particular, the contaminants can be removed by adding 400 mM AcONa at pH 4.4 (1/5 by volume). The mixture can be mixed for 15 to 20 minutes at room temperature and then sterilized by filtration using a 0.45 / 0.2 μιη filter. The invention may also use one or more sterile filtration steps, which typically involve filtration using a 0.65 μm to 0.22 μm filter and / or a 0.45 μm 0.2 μm filter.
    The precipitated material may be subjected to vacuum drying. This treatment will typically be used not to stabilize the saccharide for storage, but to dry the saccharide and remove any residual alcohol. Other precipitation and filtration steps can also be performed. Depth filtration can also be used, for example, as an alternative to centrifugation. Depth filtration will typically be used after solubilization in alcohol.
    The polysaccharide can be depolymerized to form oligosaccharides, after they have been prepared from the bacterium, but before conjugation. Depolymerization reduces the chain length of saccharides and can not be valid for GBS. Oligosaccharides may be preferred over polysaccharides for use in vaccines, and chain length has been reported to affect the immunogenicity of GBS saccharides in rabbits [4]. If depolymerization is performed, the products will generally be sized to remove short-length oligosaccharides. This can be done in various ways, including ultrafiltration followed by ion exchange chromatography. When the composition of the invention comprises a depolymerized saccharide, it is preferred that the depolymerization precedes any conjugation.
    If sialic acid residues in the GBS capsular saccharides have been de-N-acetylated, the method of the invention may comprise a re-N-acetylation step. Controlled re-N-acetylation can conveniently be accomplished using a reagent such as acetic anhydride (CH3CO) 20, for example in 5% ammonium bicarbonate [11].
    These additional steps can generally be performed at room temperature.
    The inventors have found that good yields of type II GBS capsular polysaccharide can be obtained with a process that does not require a chromatography step. As a result, the process of the invention does not include a chromatography step. In particular, the process does not include a hydrophobic interaction chromatography (HIC) step. In particular, the method does not include a step involving chromatography using phenyl sepharose.
    Preparation for conjugation
    The final purified capsular polysaccharide of the invention can be used as an antigen without further modification, for example for use in in vitro diagnostic assays, for use in immunization, etc.
    However, in the context of immunization, it is preferred to conjugate the saccharide with a carrier molecule, such as a protein. In general, covalent conjugation of saccharides with vehicles enhances the immunogenicity of saccharides because it converts them from T-independent antigens to T-dependent antigens, which allows priming for immunological memory. Conjugation is particularly useful for pediatric vaccines [eg ref. 12] and is a well-known technique [for example, reviewed in refs. 13 to 21]. The method of the invention may therefore comprise the other step of conjugating the purified saccharide with a vehicular molecule.
    Conjugation of GBS saccharides has been widely reported [for example, refer to references 22, 23, 24, 4, 25, 26, 27, 28]. The typical prior art method for conjugating GBS saccharides typically involves reductive amination of a purified saccharide to a carrier protein such as tetanus toxoid (TT) or CRM197 [23]. Reductive amination involves an amino group on the side chain of an amino acid of the carrier and an aldehyde moiety in the saccharide. Since the GBS capsular saccharides do not comprise an aldehyde group in their natural form, this is generated prior to periodate-periodate oxidation (eg between 5 and 15%, preferably about 10%) of the residues of sialic acid of the saccharide [23, 29]. Conjugate vaccines prepared in this manner have been shown to be safe and immunogenic in humans for each of the GBS Ia, Ib, II, III and V serotypes [30]. Another conjugation method involves the use of -NH 2 groups in the saccharide (either from a de-N-acetylation or after introduction of amines) together with bifunctional linkers, as described in ref. 31.
    Preferred carrier proteins are bacterial toxins or toxoids, such as diphtheria toxoid or tetanus toxoid. The CRM197 mutant of diphtheria toxin [32-34] is a particularly preferred vehicle for this purpose because it is a diphtheria toxoid. Other suitable carrier proteins include the outer membrane protein of N. meningitidis [35], synthetic peptides [36, 37], heat shock proteins [38, 39], whooping cough proteins [40, 41] , cytokines [42], lymphokines [42], hormones [42], growth factors [42], human serum albumin (preferably recombinant), artificial proteins comprising CD4 + T cell epitopes multiple human from various pathogen-derived antigens [43], such as N19 [44], protein D of strain H. influenzae [45, 46], pneumococcal surface protein PspA [47], pneumolysin [48], iron binding proteins [49], C. difficile toxin A or B [50], GBS protein [51], etc. Other suitable carrier proteins are peptidase C5a ("SCP") disclosed in WO2010 / 053986, for example, Group A streptococcus C5a peptidase (SCPA) or Group B streptococcus (SCPB).
    Vehicle binding is preferably via an -NH 2 group, for example, in the side chain of a lysine residue in a carrier protein or an arginine residue. Fixation can also be via a -SH group, for example in the side chain of a cysteine residue.
    It is possible to use more than one carrier protein, for example, to reduce the risk of vehicle suppression. As a result, different carrier proteins can be used for different GBS serotypes, for example serotype 1 saccharides for conjugating with CRM197, while serotype Ib saccharides could be conjugated with tetanus toxoid. It is also possible to use more than one carrier protein for a particular saccharide antigen, for example serotype III saccharides could be in two groups, some conjugated to CRM197 and others conjugated to tetanus toxoid. In other embodiments, GBS proteins such as SCPB described above can be used as a vehicle for one or more types of polysaccharides Ia, Ib, II, III and V or as an additional protein antigen component. in such a composition. In general, however, it is preferred to use the same carrier protein for all saccharides.
    A single carrier protein could carry more than one saccharide antigen [52, 53]. For example, a single carrier protein could be conjugated to saccharides from serotypes 1a and 1b. To achieve this goal, different saccharides can be mixed prior to the conjugation reaction. In general, however, it is preferred to have separate conjugates for each serogroup, the different saccharides being mixed after conjugation. The separated conjugates may be based on the same vehicle.
    Conjugates with a ratio of saccharide to protein (w / w) of between 1: 5 (i.e., an excess of protein) and 5: 1 (i.e., an excess of saccharide) are preferred. The ratios of 1: 2 to 5: 1 are preferred, as are the ratios of 1: 1.25 to 1: 2.5. The ratios of 1: 1 to 4: 1 are also preferred. With longer saccharide chains, an excess of saccharide weight is typical. In general, the invention provides a conjugate, wherein the conjugate comprises a streptococcus, preferably a capsular saccharide fragment of the S. agalactiae strain attached to a vehicle, wherein the weight ratio of saccharide to vehicle is at least 2: 1.
    Conjugates can be used in conjunction with a free vehicle [54]. When a given carrier protein is present both in the free form and in the conjugated form in a composition of the invention, the unconjugated form is preferably not present at more than 5% of the total amount. of the carrier protein in the composition as a whole and, more preferably, is present at less than 2% by weight.
    Any suitable conjugation reaction can be used with any suitable linker if necessary.
    The saccharide will typically be activated or functionalized prior to conjugation. Activation may involve, for example, cyanylation reagents such as CDAP (e.g., 1-cyano-4-dimethylaminopyridinium tetrafluoroborate ((55, 56, etc.)). carbodiimides, hydrazides, activated esters, norborane, p-nitrobenzoic acid, N-hydroxysuccinimide, S-NHS, EDC and TSTU (see also introduction to reference 57).
    Links via a linker group can be made using any known procedure, for example the procedures described in references 58 and 59. One type of binding involves reductive amination of the polysaccharide, coupling of the resulting amino group with end of a linker group of adipic acid, then the coupling of a protein at the other end of the adipic acid linker group [60, 61, 62]. Other linkers include B-propionamido [63], nitrophenylethylamine (ref 64), haloacyl halides [65], glycosidic linkages [66], 6-aminocaproic acid [67] and the like. ], ADH [68], C4 to C12 fragments [69], etc. As an alternative to using linkers, a forward link can be used. Direct linkages with the protein may include oxidation of the polysaccharide followed by reductive amination with the protein, as described, for example, in references 70, 71, 72.
    After conjugation, the level of unconjugated carrier protein can be measured. One way to do this involves capillary electrophoresis [73] (eg in free solution) or micellar electrokinetic chromatography [74].
    After conjugation, the level of unconjugated saccharide can be measured. One way of doing this involves HPAEC-PAD [75].
    After conjugation, a step of separating the conjugated saccharide from the unconjugated saccharide can be used. One way to separate these saccharides is to use a process that selectively precipitates a component. Selective precipitation of the conjugated saccharide is preferred to leave the unconjugated saccharide in solution, for example, by deoxycholate treatment [69].
    After conjugation, one can perform a step of measuring the molecular size and / or the molar mass of a conjugate. In particular, we can measure the distributions. One way of carrying out these measurements involves steric exclusion chromatography with detection by multi-angle light scattering photometry and differential refractometry (SEC-MALS / RI) [76].
    Combinations of conjugates
    The saccharides prepared by the methods of the invention (especially after conjugation as described above) can be mixed, for example, with each other and / or with other antigens. As a result, the method of the invention may comprise the other step of mixing the saccharide with one or more other antigens. For example, conjugates derived from GBS type II obtained by the methods of the invention may be mixed with other streptococcal conjugates, such as GBS from other serogroups, for example Ia, Ib, III and / or V.
    For example, the method of the invention may comprise another step of mixing the GBS type II capsular saccharide obtained by the purification methods of the invention (and optionally conjugated to a carrier protein) with other antigens selected from group consisting of the following: (i) a type GBS capsular saccharide (and optionally conjugated with a carrier protein); (i i) a GBS type Ib capsular saccharide (and optionally conjugated with a carrier protein); (iii) GBS type III capsular saccharide (and optionally conjugated with a carrier protein); and (iv) a GBS type V capsular saccharide (and optionally conjugated with a carrier protein). Preferably, the total amount of GBS capsular saccharides in the composition is 70 μg. Preferably, the mass ratio of saccharide GBS is: Ib: II: III: V = 1: 1: 1: 1: 1. For example, each GBS capsular saccharide is present at 1 to 30 μg per unit dose (e.g., 5 μg, 10 μg or 20 μg per unit dose).
    The composition will be produced by preparing separate conjugates (e.g., a different conjugate for each serotype) and combining the conjugates.
    The conjugates can be mixed by adding them individually to a buffered solution. A preferred solution is a phosphate buffered saline solution (final concentration of 10 mM sodium phosphate). A preferred concentration of each conjugate (measured as saccharide) in the final mixture is between 1 and 20 μg / mL, for example, between 5 and 15 μg / mL, especially around 8 μg / mL. An optional aluminum salt adjuvant may be added at this stage (e.g., to give a final concentration of Al3 + between 0.4 and 0.5 mg / mL).
    After mixing, the mixed conjugates can be filtered in a sterile medium.
    The invention relates to processes for the preparation of pharmaceutical compositions, comprising the steps of mixing (a) a saccharide of the invention (optionally in the form of a conjugate) with (b) a pharmaceutically acceptable carrier . Typical "pharmaceutically acceptable carriers" include any vehicle that does not induce the production of harmful antibodies for the individual receiving the composition. Suitable carriers are typically large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lactose, and lipid aggregates (such as droplets). oils or liposomes). These vehicles are well known to those skilled in the art. Vaccines may also contain diluents such as water, saline, glycerol, etc. In addition, auxiliary substances such as wetting or emulsifying agents, pH buffering substances, and the like. may be present. A sterile, phosphate-free, phosphate-buffered saline is a typical vehicle. A full discussion of pharmaceutically acceptable excipients is available in reference 77.
    The pharmaceutical compositions may be packaged in vials or in syringes. Syringes can be supplied with or without a needle. A syringe will comprise a single dose of the composition, while a vial may comprise a single dose or multiple doses.
    The aqueous saccharide compositions of the invention are suitable for reconstituting other vaccines from a lyophilized form. When a composition of the invention is to be used for this extemporaneous reconstitution, the invention is directed to a process for reconstituting such a lyophilized vaccine, comprising the step of mixing the lyophilized material with an aqueous composition of the invention. The reconstituted material can be used for injection.
    The compositions may include an antimicrobial agent, particularly if packaged in a multiple dose format.
    The compositions may comprise a detergent, for example Tween (polysorbate), such as TWEEN 80 (TM). Detergents are generally present at low levels (eg,> 0.01%).
    The compositions may include sodium salts (e.g., sodium chloride) to provide some tonicity. A concentration of 10 ± 2 mg / mL NaCl is typical.
    The compositions will generally comprise a buffer. A phosphate buffer is typical.
    The compositions may comprise a sugar alcohol (for example mannitol) or a disaccharide (for example sucrose or trehalose) for example in the proportion of about 15 to 30 mg / ml (for example, 25 mg / ml), in particular especially if they are to be lyophilized or if they comprise a material which has been reconstituted from a lyophilized material. The pH of the composition for lyophilization can be adjusted to about 6.1 before lyophilization.
    Conjugates may be administered together with other immunoregulatory agents. In particular, the compositions will usually comprise a vaccine adjuvant. Adjuvants that may be useful with compositions of the invention are known in the art.
    Pharmaceutical Uses The invention is also directed to a method of treating a patient comprising administering the composition to the patient. The patient may be at risk for the diseases themselves or may be a pregnant woman (maternal immunization). The patient is preferably a human. Humans can be any age, for example, younger than 2, 2 to 11, 11 to 55, older than 55, etc. The invention also relates to the composition for use in therapy. The invention also relates to the use of the composition in the manufacture of a medicament for the treatment of a disease. Preferably, the disease is influenza or pneumonia.
    The compositions will generally be administered directly to a patient. Direct delivery may be by parenteral (e.g., transcutaneous, subcutaneous, intraperitoneal, intravenous, intramuscular or interstitial tissue injection) or rectally, buccal, vaginally, optically, transdermally , intranasal, ocular, auricular, pulmonary or other mucosal administration. Intramuscular administration (e.g., thigh or upper arm) is preferred. The injection can be via a needle (for example a hypodermic needle), but needle-free injection can also be used. A typical intramuscular dose is 0.5 mL. The invention can be used to trigger systemic and / or mucosal immunity.
    A dosage treatment may be a single dose schedule or a multiple dose schedule. Multiple doses may be used in a primary immunization program and / or a booster immunization program. A main dose schedule may be followed by a booster dose schedule. Appropriate timing between priming doses (e.g., 4-6 weeks) and between priming and booster can be routinely determined.
    Bacterial infections affect various areas of the body, and the compositions can thus be prepared in various forms. For example, the compositions may be prepared in injectable form, either in solution or in liquid suspension. Solid forms suitable for solution or suspension in pre-injection liquid vehicles may also be prepared (e.g., freeze-dried composition). The composition may be prepared for topical administration, for example as an ointment, cream or powder. The composition may be prepared for oral administration, for example in the form of a tablet or capsule, or in the form of a syrup (optionally flavored). The composition may be prepared for pulmonary administration, for example in the form of an inhaler using a fine powder or spray. The composition may be prepared in the form of a suppository or pessary.
    The composition may be prepared for nasal, atrial or ocular administration, e.g., spraying, drops, gel or powder (e.g., 143 and 144). Injectable compositions are preferred. Overview
    The term "comprising" refers to the term "including" as well as "consisting of", for example, a composition "comprising" X may consist exclusively of X or may include something more, for example X + Y. "Consisting essentially of" means that the process or composition comprises additional steps and / or parts that do not materially alter the novel basic characteristics of the claimed process or composition. The term "consisting of" is generally adopted to mean that the invention as claimed is limited to the elements specifically mentioned in the claim (and may include their equivalents, so long as the doctrine of equivalents is applicable).
    The term "about" in relation to a numerical value x means, for example, x ± 10%.
    The term "substantially" does not exclude "completely", for example a composition that is "substantially free" of Y may be completely free of Y. When necessary, the word "substantially" may be omitted from the definition. of the invention.
    When the invention provides a method involving multiple sequential steps, the invention may also provide a method involving less than the total number of steps. For example, if a saccharide has already been partially purified by removing nucleic acids and / or contaminating proteins, this step may be omitted from the methods of the invention. Similarly, a contaminant removing step can be performed to provide a material amenable to detergent-mediated precipitation, but precipitation should not be performed. The precipitation step should not be carried out within the scope of the invention since the pre-precipitation material has utility as an intermediate in the preparation of saccharides and can be used, stored, exported, etc. for later use, for example, for subsequent precipitation. These different steps can be performed at very different times by different people in different places (eg in different countries).
    It should be noted that sugar rings may exist in open and closed form and that, if closed forms are illustrated in the structural formulas of the present application, open forms are also encompassed by the invention. Similarly, it should be noted that sugars may exist in the form of pyranose and furanose, and while the forms of pyranose are represented in the structural formulas of the present application, the forms of furanose are also contemplated. Various anomeric forms of sugars are also targeted.
    Examples
    To illustrate the methods of the present application, strain Streptoccus agalactiae 18RS21, which produces serotype II polysaccharides isolated from patients with GBS disease, was studied.
    Example 1
    This example shows an example of a purification protocol that provides much higher yields than was previously possible for type II GBS polysaccharides.
    Isolation and purification of GBS type II polysaccharides
    Type II natural GBS polysaccharides were extracted and purified from bacteria using the following processing steps (see Fig. 2):
    Bacterial Fermentation: A strain of GBS type II was grown to a complex medium. Any culture method may be used although a fermentation culture is preferred as described in the present application.
    Inactivation of biomass in fermentation and extraction of polysaccharides (basic treatment): if necessary, the biomass can be heated to bring it to room temperature. Sodium hydroxide (4M) was added to the biomass recovered at a final concentration of 0.8M and mixed until homogeneous. The suspension was then incubated at 37 ° C for 36 hours while mixing.
    Neutralization of the biomass: After extraction with the base treatment, a 1 M TRIS base in 50 mM final concentration was added and the suspension was mixed until homogeneous. The pH of the mixture was adjusted to 7.8 with HCl (6M) (1: 1 dilution of concentrated acid).
    Alcoholic Precipitation: 2 M CaCl 2 was added in 0.1 M final concentration (52.6 mL per 1 L of neutralized mixture) and the suspension was mixed until homogeneous. Ethanol (96% (v / v)) was added in final concentration of 30% (v / v) ethanol (428 mL per 1 L) and the suspension was mixed until homogeneous.
    Tangential Microfiltration: The mixture was diafiltered with a 0.22 μm membrane (Hydrosart Sartorius) to remove the precipitate. First, the biomass was concentrated to a working volume of 50 to 75 mL, then diafiltered with 1M NaCl buffer, 100 mM TRIS, 100 mM CaCl2, 30% EtOH (6 wash cycles). ).
    First tangential 30 kDa diafiltration: the material was diafiltered on a 30 kDa cellulose membrane (Sartorium Sartocon Hydrosart 0.1 m2) against 16 volumes of 50 mM TRIS + 0.5 M NaCl buffered at pH 8.8, then against 8 volumes of 10 mM NaPi buffered at pH 7.2.
    AcONa: the contaminants still present on the retentate were treated by addition by precipitation by adding 400 mM AcONa at pH 4.4 (1/5 volume). The mixture was gently mixed for 15-20 minutes at room temperature, then sterilized by filtration using a 0.45 / 0.2 μm filter (Sartorius Sartobran filter). The material was then stored at 2-8 ° C until needed (max 15 days).
    Second tangential 30 kDa diafiltration: the material was diafiltered on a 30 kDa cellulose membrane (Sartorius Sartocon Hydrosart 0.1 m2) against 10 volumes of 300 mM Na2Co3 + 300 mM NaCl buffered at pH 8.8.
    Filtration with Protein Adhering Filter: The material was passed through an activated carbon filter (a 3M ZetaCarbon ™ filter) to remove residual protein contaminants. Re-N-acetylation of polysaccharide: A stock solution of acetic anhydride was prepared in the following proportions: 4.15 mL of acetic anhydride per L with a ratio of acetic anhydride to ethanol of 1: 1. A stock solution of fresh acetic anhydride was added to the polysaccharide solution diluted to 2 mg / mL in a ratio of more than 22: 1 acetic anhydride to the polysaccharide repeat unit. The material was incubated under mixing for 2 hours at room temperature. The mixture was checked at the end of 2 hours to verify that it was ~ 8.8.
    Final tangential diafiltration of 10 kDa: the material was diafiltered on a 10 kDa cellulose membrane (Sartorius Sartocon Hydrosart 0.1 m2) against 16 volumes of KPi buffered at a rate of 10 mM at pH 7.2. Purified PSII was filtered at 0.22 μm with a disposable syringe filter (NALGENE®, PES) and stored at +4 / 8 ° C.
    Analytical processes
    Wet chemical tests: The saccharide content was determined by the sialic acid wet chemical test [78]. The sample was hydrolysed in HCl at 80 ° C for 90 minutes, neutralized with NaOH and injected into a DIONEX ™ system. The data is processed by the CHROMELEON ™ software. The saccharides were eluted using a linear seven-minute gradient of 90:10 to 60:40 with 0.1 M NaOH, 0.1 M Na acetate: 0.1 M NaOH, 0.5 M of NaNO3 on a CarboPac PA1 column with a PA1 guard at a flow rate of 1.0 mL / min. Free sialic acid was determined by injecting the solubilized polysaccharide sample into water at 1.0 mg / mL without hydrolyzing the sample. In this way it was possible to separate the free sialic acid from the bound sialic acid. In the polysaccharide sample, free sialic acid is not detected. The peak at the regeneration step was the unhydrolyzed polysaccharide. Free sialic acid is an important parameter because it is related to an immune response.
    The residual protein content was determined by a MicroBCA (TM) commercial kit (Pierce). The residual nucleic acid content was determined following the method published in reference 79.
    The residual B group polysaccharide content was determined by determining the rhamnose residues and using a method based on HPAEC-PAD analysis. Rhamnose is a specific saccharide in Group B carbohydrates that is not found in typical polysaccharides and has been used to determine the concentration of contaminant carbohydrate residues after purification of capsular polysaccharides.
    Samples and standards were hydrolysed in 2 N TFA at 100 ° C for 3.0 hours, then evaporated in a SpeedVac and reconstituted with 450 μL of H 2 O. The range of the standard rhamnose curve is 1.0 to 10.0 μg / mL. Chromatographic conditions were a CarboPac PA1 column with a PA1 guard at a rate of 1.0 mL / min 12 mM NaOH for 15 minutes followed by 5 minutes of regeneration with 500 mM NaOH and then rebalancing in 12 mM NaOH for 25 min. minutes. Results and discussion
    The new purification method (Fig. 2) provides improvements for purifying GBS type II polysaccharides. Compared to the prior art process where a 30 kDa cellulose membrane is used in the final filtration stage, the new purification process recovers a much higher yield, while all the main potential contaminants (proteins nucleic acids and polysaccharide of group B) remain low (compare the "post-N-acetylation ret UF 30K" and "post-N-acetylation perm UF30K and ret 10K pool" rows in Table 1, page 25). The new purification method can be used to manufacture clinical and commercial materials derived from these capsular polysaccharides.
    The new purification method also provides reproducible yields (Table 2), identity, compliance and purity (Table 3) at each purification step between different batches.
    Table 2. Yield between different batches at each stage of the purification process
    Table 3. Identity, Conformity and Purity Between Different Batches Using the Purification Process of the Invention
    Example 2
    The relative molecular weight and particle size of the GBS type II capsular polysaccharide were studied. The particle sizes of GBS type Ia, Ib, III and V capsular polysaccharides were also determined.
    Analytical processes
    NMR Analysis: Purified polysaccharide samples were prepared by dissolving the powder in 1 mL of deuterium oxide (D2O, Aldrich) in a uniform concentration. Aliquots (750 μl) of sample were transferred to 5 mm NMR tubes (Wilmad). 1 H NMR experiments were recorded at 25 ° C on a 600 MHz Bruker spectrometer and using a 5 mm wide band probe (Bruker). For the acquisition and processing of data, the software suite XWINNMR (Bruker) was used. 1-D proton NMR spectra were collected using a standard pulse test with 32 scans. The transmitter has been tuned to the HDO frequency (4.79 ppm). 1 H NMR spectra were obtained quantitatively using a total recycle time to ensure full recovery of each signal (5 x T1 longitudinal relaxation time).
    2-D homo- and heterocorrelation NMR spectra were recorded to affect the 1-D proton NMR profiles. The assignment of a peak was also confirmed by comparison with the published data [80].
    Static Light Diffusion (MALLS): This technique determines the RMS (RMS) or "radius of gyration" Rg of a molecule. This is the average distance in mass of each diffusion center from the center of gravity of the molecule. This process takes into account the intensity of the average scattered light and is independent of the solvent and time (refer to Ref 81).
    Dynamic Light Diffusion (DLS): This technique measures the Rh hydrodynamic radius of a molecule. It is the radius of a sphere having the same diffusion coefficient as the molecule. This process takes into account fluctuations in the intensity of scattered light and is dependent on the time and viscosity of the solvent (refer to Ref 81). Results and discussion
    The average molecular weight for type II GBS capsular polysaccharide estimated by size exclusion chromatography was ~ 270 to 420 kDa (Table 4). The structural identity of GBS type II capsular polysaccharides was confirmed by 1H NMR spectroscopy (data not shown).
    Table 4. Molecular Weight of a Type II GBS Capsular Polysaccharide
    Particle size measurements are provided in Table 5 below. In compact objects, the mass is close to the center of the mass. Rg is smaller than Rh and Rg / Rh <l. For an extended object, Rg 'is strongly influenced by the distant masses, but the hydrodynamic radius Rh is less strongly influenced. The ratio of Rg to Rh increases as the object becomes less compact (Rg / Rh> 1).
    Table 5. Particulate sizes of GBS capsular saccharides determined by MALLS and DLS
    The GBS type-II capsular polysaccharide purified by bacterial growth of strain 18RS21 had a hydrodynamic radius (apparent MW in steric exclusion chromatography of flow through a filtration membrane) lower than the expected value considering its absolute PM (> 200 kDa as estimated by SEC-MALLS analysis).
    The unusual behavior of a GBS type II capsular saccharide compared to other GBS types of capsular saccharides (i.e., Ia, Ib, III and V) is probably due to the different arrangement of the monosaccharides constituting the recurring pattern. As an example, while for GBS type Ia and Ib capsular saccharides, the branch is composed of three monosaccharides (apart from the five totally contained sugars), for a type II GBS capsular saccharide, the branch contains only one monosaccharide. The shorter branch probably confers a more linear conformation and, consequently, reduced steric hindrance. SUMMARY The final tangential filtration step of the conventional protocol for the purification of GB'S capsular saccharides is usually performed by a 30 kDa cut-off filter (for example, refer to No. 2). The inventors determined the average molecular weight for the type II GBS capsular polysaccharide which would be ~ 270 to 420 kDa, so that it was expected that this capsular polysaccharide would be retained by a 30 kDa filter. However, as shown in Example 1, it was surprisingly found that a large amount (~ 50%) of the type II GBS capsular polysaccharide passed through the 30 kDa filter at the final tangential filtration stage of the purification protocol (Table 1). The inventors have found, not surprisingly, that the type II GBS capsular polysaccharide has a lower hydrodynamic radius compared to other GBS types of capsular saccharides (i.e., Ia, Ib, III and V). As a result, the replacement of the filter in the final tangential filtration stage of the flow of the conventional purification protocol with a lower PM cutoff filter, for example by a 10 kDa cut-off filter, is particularly advantageous. advantageous for retaining the GBS type II capsular polysaccharide. The method of the invention thus provides a higher yield of the GBS type II capsular polysaccharide.
    It is understood that the invention has been described by way of example only and that modifications may be made thereto while remaining within the scope and spirit of the invention. References [1] Ada &amp; Isaacs (2003) Clin Microbiol Infect 9: 79-85.
    [2] WO 2009/081276.
    [3] Deng et al. (2000) J. Biol Chem 275: 7497-04.
    [4] Paoletti et al. (1992) Infect Immun 60: 4009-14.
    [5] Lewis et al. (2004) PNAS USA 101: 11123-8.
    [6] WO98 / 32873.
    [7] Frash (1990) p. 123-145 of Advances in Biotechnological Processes vol. 13 (eds., Mizrahi & Van Wezel).
    [8] EP 0072513.
    [9] WO 2006/082527.
    [10] US Patent 6248570.
    [11] Baker et al. (2004) J Infect Dis 189: 1103-12.
    [12] Ramsay et al. (2001) Lancet 357 (9251): 195-196.
    [13] Lindberg (1999) Vaccine 17 Suppl 2: S28-36.
    [14] Buttery &amp; Moxon (2000) J R Coll Physicians Lond 34: 163-68.
    [15] Ahmad &amp; Chapnick (1999) Infect Dis Clin North Am 13: 113-33, vii.
    [16] Goldblatt (1998) J. Med. Microbiol, 47: 563-7.
    [17] European patent 0477508.
    [18] US Patent 5,306,492.
    [19] WO 98/42721.
    [20] Dick et al. in Conjugate Vaccines (Cruse et al.) Karger, Basel, 1989, 10: 48-114.
    [21] Hermanson Bioconjugae Techniques, Academic Press, San Diego (1996) ISBN: 0123423368.
    [22] Ada &amp; Isaacs (2003) Clin Microbiol Infect 9: 79-85.
    [23] Paoletti et al. (1990) J Biol Chem 265: 18278-83.
    [24] Wessels et al. (1990) J Clin Invest 86: 1428-33.
    [25] Paoletti et al. (1992) J Clin Invest 89: 203-9.
    [26] Wessels et al. (1987) Proc Natl Acad Sci USA 84: 9170-4.
    [27] Wang et al. (2003) Vaccine 21: 1112-7.
    [27] Wessels et al. (1995) J Infect Dis 171: 879-84.
    [28] Wessels et al. (1993) Infect Immun 61: 4760-6.
    [29] US Patent 4356170.
    [30] Paoletti &amp; Kasper (2003) Expert Opin Biol Ther 3: 975-84.
    [31] WO 2006/082530.
    [32] Anonymous (Jan 2002) Research Disclosure, 453077.
    [33] Anderson (1983) Infect Immun 39 (1): 233-8.
    [34] Anderson et al. (1985) J Clin Invest 76 (1): 52-9.
    [35] EP-A-0372501.
    [36] EP-A-0378881.
    [37] EP-A-0427347.
    [38] WO 93/17712.
    [39] WO 94/03208.
    [40] WO 98/58668.
    [41] EP-A-0471177.
    [42] WO 91/01146.
    [43] Falugi et al. (2001) Eur J Immunol 31: 3816-24.
    [44] Baraldo et al. (2004) Infect Immun 72 (8): 4884-7.
    [45] EP-A-0594610.
    [46] WO 00/56360.
    [47] WO 02/091998.
    [48] Kuo et al. (1995) Infect Immun 63: 2706-13.
    [49] WO 01/72337.
    [50] WO 00/61761.
    [51] WO 2004/018646.
    [52] WO 99/42130.
    [53] WO 2004/011027.
    [54] WO 96/40242.
    [55] Lees et al. (1996) Vaccine 14: 190-98.
    [56] WO 95/08348.
    [57] WO 98/42721.
    [58] US 4882317.
    [59] US 4695624.
    [60] EP 0477508.
    [61] Porro and coli. (1985) Mol. Immunol. 22: 907-19.
    [62] EP 0208375A.
    [63] WO 00/10599.
    [64] Gever et al. Med. Microbiol. Immunol., 165: 171-288 (1979).
    [65] US 4057685.
    [66] US 4673574; US 4761283; US 4808700.
    [67] US 4459286.
    [68] US 4965338.
    [69] US 4663160.
    [70] US 4761283.
    [71] US 4356170.
    [72] WO 2012/035519.
    [73] Lamb et al. (2000) Dev. Biol. (Basel) 103: 251-58.
    [74] Lamb et al. (2000) Journal of Chromatography A 894: 311-18.
    [75] Lei et al. (2000) Dev. Biol. (Basel) 103: 259-64.
    [76] Ambra et al. (2000) Dev. Biol. (Basel) 103: 241-42.
    [77] Gennaro (2000) Remington: The Science and Practice of Pharmacy. 20th edition, ISBN: 0683306472.
    [78] Svennerholm, L. Biochem. Biophys. Acta 1957, 24, 604.
    [79] Sheldon, E.L .; et al. Biochem. Biophys. Res. Comm. 1989, 156 (1), 474.
    [80] Michon, F.; Chalifour, R.; Feldman, R.; Wessels, M.; Kasper, D.L .; Gamian, A.; Pozsgay, V.; Jennings, H.J. Infect Immun 1991, 59, 1690 and related papers.
    [81] Jones C. Anais da Academia Brasileira de Ciências (2005) 77 (2): 293-324 (Annals of the Brazilian Academy of Sciences).
    Table 1. Characterization at each stage of the purification process of Example 1
    权利要求:
    Claims (17)
    [1]
    A method of purifying a type II GBS capsular polysaccharide comprising (i) a microfiltration step which uses a membrane <0.65 μm; (ii) a filtration step that uses a membrane with a cut-off of less than about 30 kDa; (iii) a filtration step which uses a 0.45 to 0.22 μm membrane; (iv) a filtration step that uses a membrane with a cut-off of less than about 30 kDa; (v) a filtration step that uses a protein-adhering filter; (vi) a filtration step that uses a membrane with a cutoff of about 10 kDa; (vii) a microfiltration step that uses a disposable syringe filter of 0.22 μm.
    [2]
    The process of claim 1, wherein the filtering step results in diafiltration.
    [3]
    3. Method according to any one of the preceding claims, wherein the filtration is transverse or tangential.
    [4]
    The method of any of the preceding claims, wherein the filtering step utilizes a cellulose membrane.
    [5]
    The method of any of the preceding claims, wherein one or more additional steps are or are performed after the filtration step (vi), including precipitation of the purified capsular polysaccharide.
    [6]
    The method according to any one of the preceding claims, wherein one or more additional steps are or are performed after the filtration step (vi), comprising conjugating the capsular polysaccharide with a carrier protein, for example diphtheria toxoid. , tetanus toxoid or CRM197.
    [7]
    The method of any of the preceding claims, wherein one or more additional steps are or are performed after the filtration step (vi), comprising formulating a vaccine with the capsular polysaccharide as a component.
    [8]
    A process according to any one of the preceding claims, wherein one or more additional steps are or are performed after the filtration step (vi), comprising mixing with one or more capsular polysaccharides of a GBS serotype selected from group consisting of la, Ib, III, IV, V, VI, VII and VIII, optionally in which the capsular polysaccharide (s) is or are conjugated with one or more carrier proteins, for example diphtheria toxoid, tetanus toxoid or the CRM197.
    [9]
    The method of any one of the preceding claims, wherein each filtration step uses a different buffer.
    [10]
    The method of claim 9, wherein the buffers are selected from buffers comprising NaPi, Na2CO3 or KPi.
    [11]
    The method of any one of the preceding claims, wherein step (i) is buffered with a buffer comprising NaPi; step (ii) is buffered with a buffer comprising Na2CO3; and step (iii) is buffered with a buffer comprising KPi.
    [12]
    The method of claim 1, wherein all steps are performed in sequence.
    [13]
    The method of claim 1 wherein step (iii) comprises adding AcONa.
    [14]
    The method of any one of the preceding claims, wherein step (v) uses a charcoal filter.
    [15]
    The process according to any one of the preceding claims, wherein the re-N-acetylation of the polysaccharide is carried out before the filtration step (vi).
    [16]
    The method of any one of the preceding claims, wherein the method further comprises: (a) providing a crude isolate containing the capsular polysaccharide; (b) removing an alcoholic precipitate formed by contacting the crude isolate with an alcoholic solution; (c) performing one or more filtration steps.
    [17]
    17. A composition comprising a type II GBS capsular polysaccharide obtainable by the method of any one of the preceding claims.
    类似技术:
    公开号 | 公开日 | 专利标题
    CA2708878C|2017-01-17|Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
    JP2015147806A|2015-08-20|Conjugation of streptococcal capsular saccharides
    AU2006211049B2|2012-06-07|Purification of streptococcal capsular polysaccharide
    US8598337B2|2013-12-03|Method for purifying polysaccharides
    KR101161033B1|2012-06-28|Process for producing a capsular polysaccharide for use in conjugate vaccines
    AU2006310176B2|2012-11-29|Fed batch culture methods for Streptococci
    TW201945028A|2019-12-01|Multivalent pneumococcal polysaccharide-protein conjugate composition
    CN104736180A|2015-06-24|Meningococcus serogroup X conjugate
    CN111757753A|2020-10-09|Multivalent pneumococcal polysaccharide-protein conjugate composition
    BE1023297B1|2017-01-26|PURIFICATION OF STREPTOCOCCAL CAPSULAR POLYSACCHARIDE
    BE1025162A9|2019-01-03|PURIFICATION PROCESS FOR CAPSULAR POLYSACCHARIDES
    HUE029265T2|2017-02-28|Purification method for carbohydrate from group a streptococcus
    AU2013202943A1|2013-05-02|Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
    CN113966234A|2022-01-21|Production of conjugates
    同族专利:
    公开号 | 公开日
    EP3233927A1|2017-10-25|
    US20170348408A1|2017-12-07|
    WO2016097147A1|2016-06-23|
    BE1023297A1|2017-01-26|
    EP3034516A1|2016-06-22|
    AR103082A1|2017-04-12|
    US10172928B2|2019-01-08|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    WO1999032653A1|1997-12-23|1999-07-01|North American Vaccine, Inc.|Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugates vaccines|
    WO2006082527A2|2005-02-01|2006-08-10|Novartis Vaccines And Diagnostics Srl|Purification of streptococcal capsular polysaccharide|
    US20070154492A1|2006-01-13|2007-07-05|Baxter International Inc.|Method for Purifying Polysaccharides|
    WO2009081276A2|2007-12-20|2009-07-02|Novartis Ag|Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom|
    US4057685A|1972-02-02|1977-11-08|Abbott Laboratories|Chemically modified endotoxin immunizing agent|
    US4356170A|1981-05-27|1982-10-26|Canadian Patents & Development Ltd.|Immunogenic polysaccharide-protein conjugates|
    BE889979A|1981-08-14|1982-02-15|Smith Kline Rit|PROCESS FOR THE PREPARATION OF PURIFIED ANTIGENIC CAPSULAR BACTERIAL POLYSACCHARIDES, PRODUCTS OBTAINED AND THEIR USE|
    US4673574A|1981-08-31|1987-06-16|Anderson Porter W|Immunogenic conjugates|
    US4761283A|1983-07-05|1988-08-02|The University Of Rochester|Immunogenic conjugates|
    US4459286A|1983-01-31|1984-07-10|Merck & Co., Inc.|Coupled H. influenzae type B vaccine|
    US4663160A|1983-03-14|1987-05-05|Miles Laboratories, Inc.|Vaccines for gram-negative bacteria|
    US4695624A|1984-05-10|1987-09-22|Merck & Co., Inc.|Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency|
    US4882317A|1984-05-10|1989-11-21|Merck & Co., Inc.|Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency|
    US4808700A|1984-07-09|1989-02-28|Praxis Biologics, Inc.|Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers|
    IT1187753B|1985-07-05|1987-12-23|Sclavo Spa|GLYCOPROTEIC CONJUGATES WITH TRIVALENT IMMUNOGENIC ACTIVITY|
    NL8802046A|1988-08-18|1990-03-16|Gen Electric|POLYMER MIXTURE WITH POLYESTER AND ALKANE SULFONATE, OBJECTS THEREFORE.|
    DE3841091A1|1988-12-07|1990-06-13|Behringwerke Ag|SYNTHETIC ANTIGENS, METHOD FOR THEIR PRODUCTION AND THEIR USE|
    ES2055785T3|1989-01-17|1994-09-01|Eniricerche Spa|SYNTHETIC PEPTIDES AND THEIR USE AS UNIVERSAL VEHICLES FOR THE PREPARATION OF IMMUNOGENOUS CONJUGATES SUITABLE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES.|
    KR920703114A|1989-07-14|1992-12-17|원본미기재|Cytokines and Hormone Carriers for Conjugate Vaccines|
    IT1237764B|1989-11-10|1993-06-17|Eniricerche Spa|SYNTHETIC PEPTIDES USEFUL AS UNIVERSAL CARRIERS FOR THE PREPARATION OF IMMUNOGENIC CONJUGATES AND THEIR USE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES.|
    SE466259B|1990-05-31|1992-01-20|Arne Forsgren|PROTEIN D - AN IGD BINDING PROTEIN FROM HAEMOPHILUS INFLUENZAE, AND THE USE OF THIS FOR ANALYSIS, VACCINES AND PURPOSE|
    AT128628T|1990-08-13|1995-10-15|American Cyanamid Co|FIBER HEMAGGLUTININE BY BORDETELLA PERTUSSIS AS A CARRIER FOR CONJUGATED VACCINE.|
    US5153312A|1990-09-28|1992-10-06|American Cyanamid Company|Oligosaccharide conjugate vaccines|
    IT1262896B|1992-03-06|1996-07-22|CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES.|
    IL102687A|1992-07-30|1997-06-10|Yeda Res & Dev|Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them|
    DE122009000058I1|1993-09-22|2009-12-31|Jackson H M Found Military Med|PROCESS FOR ACTIVATING SOLUBLE CARBOHYDRATE BY USING NEW CYANYLATION REAGENTS FOR PREPARING IMMUNOGENIC CONSTRUCTS|
    DE4432628B4|1994-09-14|2008-01-10|Sartorius Biotech Gmbh|Dead-end filtration unit for separating substances with membrane adsorbers|
    HU9802199A3|1995-06-07|1999-07-28|Smithkline Beecham Biolog|Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein and use of|
    AU727593B2|1997-01-24|2000-12-14|Schweiz. Serum- & Impfinstitut Bern|Novel method for the isolation of polysaccharides|
    US6299881B1|1997-03-24|2001-10-09|Henry M. Jackson Foundation For The Advancement Of Military Medicine|Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts|
    GB9713156D0|1997-06-20|1997-08-27|Microbiological Res Authority|Vaccines|
    US7018637B2|1998-02-23|2006-03-28|Aventis Pasteur, Inc|Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines|
    CN1263510C|1998-08-19|2006-07-12|巴克斯特健康护理股份有限公司|Immunogenic beta-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an N-acryloylated polysaccharide|
    KR100642044B1|1999-03-19|2006-11-10|글락소스미스클라인 바이오로지칼즈 에스.에이.|Vaccine|
    JP2002541808A|1999-04-09|2002-12-10|テクラブ，インコーポレイテッド|Recombinant toxin A protein carrier for polysaccharide conjugate vaccine|
    GB0007432D0|2000-03-27|2000-05-17|Microbiological Res Authority|Proteins for use as carriers in conjugate vaccines|
    AU2002309706A1|2001-05-11|2002-11-25|Aventis Pasteur, Inc.|Novel meningitis conjugate vaccine|
    AU2003257003A1|2002-07-30|2004-02-16|Baxter Healthcare S.A.|Chimeric multivalent polysaccharide conjugate vaccines|
    EP1597348A4|2002-08-26|2010-03-31|Novartis Vaccines & Diagnostic|Conserved and specific streptococcal genomes|
    GB0502095D0|2005-02-01|2005-03-09|Chiron Srl|Conjugation of streptococcal capsular saccharides|
    WO2009118331A1|2008-03-28|2009-10-01|Research Foundation For Medical Devices|Method of viral inactivation of biological fluids by solvent/detergent-treatment|
    NZ614064A|2008-11-05|2015-04-24|Wyeth Llc|Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal disease|
    GB201101665D0|2011-01-31|2011-03-16|Novartis Ag|Immunogenic compositions|
    WO2015169774A1|2014-05-07|2015-11-12|Glaxosmithkline Biologicals S.A.|Purification of secreted polysaccharides from s. agalactiae|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    EP14199441.8A|EP3034516A1|2014-12-19|2014-12-19|Purification of streptococcal capsular polysaccharide|
    EP14199441.8|2014-12-19|
    [返回顶部]